SYRE250117C15000
- 11.10
- 0.000.00%
Spyre Therapeutics Newsroom
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $70
Promising Potential of Spyre Therapeutics' SPY002 Drives Buy Rating Amid Robust Anti-TL1A Market
Spyre Therapeutics Analyst Ratings
JonesTrading Initiates Spyre Therapeutics(SYRE.US) With Hold Rating
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $71
Baird Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $65
Spyre Therapeutics Is Maintained at Outperform by Baird
Spyre Therapeutics Analyst Ratings
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $70
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
TD Cowen Maintains Spyre Therapeutics(SYRE.US) With Buy Rating
TD Cowen Maintains Spyre Therapeutics(SYRE.US) With Buy Rating
Spyre Therapeutics Is Maintained at Buy by Guggenheim
Spyre Therapeutics Analyst Ratings
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Baird Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40
Promising Advancements in Spyre Therapeutics' Programs Drive Buy Rating